西达苯胺联合R-DHAP方案治疗复发/难治性弥漫大B细胞淋巴瘤的临床疗效  

Clinical Efficacy and Survival Analysis of Chidamide Combined with R-DHAP Regimen in the Treatment of Relapsed/Refractory Diffuse Large B-cell Lymphoma

作　　者：王晓伟[1] 李宁 刘婷[2] 王亚琦 WANG Xiaowei;LI Ning;LIU Ting(Emergency Center,the Second Affiliated Hospital of Shaanxi University of Chinese Medicine,Xianyang Shaanxi 712000)

机构地区：[1]陕西中医药大学第二附属医院急救中心,陕西咸阳712000 [2]陕西中医药大学第二附属医院耳鼻喉科,陕西咸阳712000 [3]西安国际医学中心医院药学部,陕西西安710100 [4]西安国际医学中心医院药剂科,陕西西安710100

出　　处：《医学临床研究》2024年第4期537-539,543,共4页Journal of Clinical Research

摘　　要：【目的】探讨西达苯胺联合R-DHAP方案治疗复发/难治性弥漫大B细胞淋巴瘤(DLBCL)的临床疗效。【方法】78例复发/难治性DLBCL患者,随机分为观察组和对照组。对照组采用R-DHAP方案治疗,观察组采用西达苯胺联合R-DHAP方案治疗。比较两组肿瘤患者体力状况(ECOG)评分,临床疗效,血清血管内皮生长因子(VEGF)、β2-微球蛋白(β2-MG)水平,药物不良反应以及无进展生存时间。【结果】治疗3个疗程后,两组ECOG评分较治疗前均降低(P<0.05),且观察组低于对照组(P<0.05);观察组的客观缓解率高于对照组(P<0.05);两组血清VEGF、β2-MG水平均较治疗前降低(P<0.05),且观察组低于对照组(P<0.05)。两组不良反应发生率比较,差异无统计学意义(P>0.05)。观察组和对照组患者中位无进展生存时间分别为20.60个月和15.18个月,两组比较,差异有统计学意义(P<0.05)。【结论】西达苯胺联合R-DHAP方案治疗复发/难治性DLBCL患者能够改善临床症状,疗效确切,同时可以降低血清VEGF、β2-MG水平,延长患者生存时间,且安全可靠。【Objective】To explore the efficacy of chidamide combined with R-DHAP regimen in the treatment of relapsed/refractory diffuse large B-cell lymphoma(DLBCL).【Methods】A total of 78 patients with relapsed/refractory DLBCL were selected and randomly divided into the observation group and the control group.The control group was treated with R-DHAP regimen,and the study group was treated with chidamide combined with R-DHAP regimen.The ECOG score,clinical efficacy,serum vascular endothelial growth factor(VEGF),β2-microglobulin(β2-MG)levels,adverse drug,and progression-free survival time reactions were compared between the two groups.【Results】After 3 courses of treatment,the ECOG scores of both groups were lower(P<0.05),which the study group showed lower than the control group(P<0.05).The objective remission rate of the observation group was higher than that of the control group(P<0.05).After 3 courses of treatment,the levels of serum VEGF andβ2-MG in both groups were lower than those before treatment(P<0.05);And the levels of serum VEGF andβ2-MG in the observation group were lower than those in the control group(P<0.05).The incidence of adverse reactions in both groups was not statistically significant(P>0.05).The median progression-free survival curves between the observation group and the control group was 20.60 months and 15.18 months,respectively,which was statistically significant difference(P<0.05).【Conclusion】Chidamide combined with R-DHAP regimen in the treatment of patients with relapsed/refractory DLBCL can improve clinical symptoms and enhance the curative effect.It can reduce the levels of serum VEGF andβ2-MG,prolong the survival time of patients,and it is safe and reliable.

关 键 词：淋巴瘤 大B细胞 弥漫性/药物疗法 抗肿瘤联合化疗方案 治疗结果 

分 类 号：R733.41[医药卫生—肿瘤]